IL-6, which is a practical biomarker of systemic inflammation and adverse outcomes of acute COVID-19, may serve as a useful predictor of LC after a time window of 4-weeks post-infection, informing on the “early stage” of LC [173]. The gene discussed is IL6; the disease is COVID-19.